SAN DIEGO, Sept. 1, 2016 /PRNewswire/ -- OncoSec
Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company
developing DNA-based intratumoral cancer immunotherapies, announced
today that members of its leadership team will be making
presentations at several high-profile events in September,
including: Rodman & Renshaw 18th Annual Global
Investment Conference and Bioelectrics 2016: 13th
International Bioelectrics Symposium.
Rodman & Renshaw 18th Annual Global Investment
Conference
Punit Dhillon
will present a corporate overview at the Rodman & Renshaw
18th Annual Global Investment Conference on September 12 at 10:00 AM
ET at The Lotte New York Palace Hotel in New York City. To view to the live webcast,
please access the following link at the time of the presentation:
http://wsw.com/webcast/rrshq26/oncs/. An archived version of the
webcast will be available for 90 days on OncoSec's website:
http://www.oncosec.com.
This conference brings together growth companies and a vast
audience of financial and strategic investors for in-depth
corporate presentations as well as to facilitate one-on-one
investor and networking meetings. The conference will focus on
tracks dedicated to healthcare; natural resources; technology,
media and telecommunications; clean tech. For more information,
please visit: http://www.rodm.com.
Bioelectrics 2016: 13th International Bioelectrics
Symposium
Richard Connolly,
PhD, Director of Bioengineering at OncoSec, will present an invited
lecture entitled: "Adaptive Electroporation Technology for
Intratumoral Immunotherapy" at the 13th International
Bioelectrics Symposium on September
12 at 9:45 AM CEST at the
Penta Hotel in Rostock, Germany.
The symposium presents a forum to discuss research and
applications regarding the interactions of electrical stimuli with
living cells, in particular pulsed electric fields and non-thermal
plasmas. Research topics and applications covered during the
symposium include: biological responses; biophysics and
biochemistry of interaction mechanisms; exposure devices and
methods, and cancer treatment and tumor ablation. For more
information, please visit: http://www.bioelectrics2016.org/.
About OncoSec Medical Incorporated
OncoSec is a
biotechnology company developing DNA-based intratumoral
immunotherapies with an investigational technology,
ImmunoPulse®, for the treatment of cancer.
ImmunoPulse® is designed to enhance the local delivery
and uptake of DNA-based immune-targeting agents, such as IL-12. In
Phase I and II clinical trials, ImmunoPulse® IL-12 has
demonstrated a favorable safety profile and evidence of anti-tumor
activity in the treatment of various solid tumors and has shown the
potential to reach beyond the site of local treatment to initiate a
systemic immune response. ImmunoPulse® IL-12, OncoSec's
lead program, is currently in clinical development for several
indications, including metastatic melanoma and triple-negative
breast cancer. The program's current focus is on the significant
unmet medical need in patients with melanoma who are refractory or
non-responsive to anti-PD-1/PD-L1 therapies. In addition to
ImmunoPulse® IL-12, the Company is also identifying and
developing new immune-targeting agents for use with the
ImmunoPulse® platform. For more information, please
visit www.oncosec.com.
CONTACT:
Mary
Marolla
OncoSec Medical Incorporated
855-662-6732
media@oncosec.com
Logo -
http://photos.prnewswire.com/prnh/20120905/LA68078LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/oncosec-to-present-at-scientific-and-investment-conferences-in-september-300321124.html
SOURCE OncoSec Medical Incorporated